Assessment of the remdesivir use for the treatment of COVID-19
DOI:
https://doi.org/10.5281/zenodo.11492896Keywords:
antivirals, covid-19, pharmacological actions, pharmacokineticsAbstract
Introduction: remdesivir is a broad-spectrum antiviral prodrug that is used for the treatment of patients hospitalized for COVID-19.
Objective: to assess the available scientific evidence on the use of remdesivir in the treatment of COVID-19.
Methods: a review of the bibliography was carried out in the databases available in Spanish and English from the Virtual Health Library, MEDLINE, Lilacs, SciELO, EBSCO and the Google Scholar search engine from 2018 to 2021. 50 articles were selected with the needed information.
Development: therapies with nucleotide/nucleoside inhibitors directed against DNA and RNA polymerase could become the core treatments of antiviral therapy. When remdesivir is converted to an active metabolite, it causes viral RNA chain termination and inhibits viral replication, which has been confirmed in pre-clinical studies. The information available from clinical trials is controversial, however, it has been shown that it improves patient recovery time and survival. Although it has shown a favorable safety profile, adverse reactions are still being reported. The five-day treatment scheme shows good efficacy and a lower rate of interruption due to adverse effects; the inhaled route appears to improve the bioavailability of remdesivir in lung tissues.
Conclusions: remdesivir is recommended for the treatment of hospitalized patients with COVID-19 and oxygen requirements, however, more research in humans is required to confirm its clinical efficacy in these patients.
Downloads
References
Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J. Infect. Public Health [Internet]. 2020 [citado 23 Mar 2021];13(5):667-73. Disponible en: https://www.sciencedirect.com/science/article/pii/S1876034120304329
Castella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, Evaluation and Treatment of coronavirus (Covid-19). NLM. En: StatPearls [Internet]. Florida: StatPearls Publishing. 2021 [citado 20 Abr 2021]; Disponible en: https://apps.dtic.mil/sti/pdfs/AD1127230.pdf
Daou F, Sleymane GA, Brado DA, Khanafer N, Tobaiqy M, Faraj AA. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of Covid-19. Int.
J. Environ. Res. Public Health [Internet]. 2021 [citado 20 Abr 2021];18:[aprox. 16 p.]. Disponible en: https://mdpi-res.com/d_attachment/ijerph/ijerph-18-00955/article_deploy/ijerph-18-00955.pdf?version=1611325090
Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune response in convalescent patients following symptomatic COVID-19. Nat Comm [Inetrnet]. 2021 [citado 20 Abr 2021];12:[aprox. 9 p.] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985370/pdf/41467_2021_Article_22034.pdf
Jirjees F, Saad AK, Hano ZA, Hatahet T, Obaidi HA, Bashi YD. COVID-19 Treatment Guidelines: Do They Really Reflects Best Medical Practices to Manage the Pandemic? Inf Dis Rep [Internet]. 2021 Feb 24 [citado 15 May 2021];13(2):259-84. Disponible en: https://mdpi-res.com/d_attachment/idr/idr-13-00029/article_deploy/idr-13-00029.pdf?version=1617938877
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et. al. Remdesivir: A Review of its Discovery and Development Leading to Emergency Use Authorization for Treatment of Covid-19. ACS Cent Sci [Internet]. 2020 [citado 13 Abr 2021];6(5):672-83. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202249/pdf/oc0c00489.pdf
Wang C, Wang Z, Wang G, Lau JAY, Zang K, Li W. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther [Internet]. 2021 [citado 13 Abr 2021];6:[aprox. 14 p.]. Disponible es: https://www.nature.com/articles/s41392-021-00527-1.pdf
Díaz-Catrillón F, Toro-Montoya AI. SARS-CoV-2/Covid-19: el virus la enfermedad y la pandemia. EMC [Internet]. 2020 [citado 13 Abr 2021];24(3):183-205. Disponible en: https://docs.bvsalud.org/biblioref/2020/05/1096519/covid-19.pdf
National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH [Internet]. [citado 13 Abr 2021]. Disponible en: https://www.covid19treatmentguidelines.nih.gov/
Sun D. Remdesivir for treatment of Covid-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefits. AAPS J [Internet]. 2020 [citado 13 Abr 2021];22(4):[aprox. 6 p.]. Disponible es: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250281/pdf/12248_2020_Article_459.pdf
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in Covid-19; A narrative review for emergency providers. Am J Emerg Med [Internet]. 2020 [citado 13 Abr 2021];38(7):1488-93. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158837/pdf/main.pdf
Gómez JT, Dieguez RG, Pérez MA. Alternativas terapéuticas para el manejo de la Covid-19. Ciencias Clínicas y Patológicas. Rev haban cienc méd [Internet]. 2020 [citado 13 Abr 2021];19(Supl. 1):[aprox. 15 p.]. Disponible en: http://scielo.sld.cu/pdf/rhcm/v19s1/1729-519X-rhcm-19-s1-e3328.pdf
Lu G, Zhang X, Zheng W, Sun J, Hua Lan, Xu L, et al. Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA Dependent RNA Polymerase. Antimicrob Agents Chemother [Internet]. 2020 [citado 13 Abr 2021];65(1):e1508-20. Disponible en: https://journals.asm.org/doi/pdf/10.1128/AAC.01508-20
Kumar I. A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus diseases. Journal of Drug Delivery and Therapeutics [Internet]. 2021 [citado 13 Abr 2021];11(1):121-29. Disponible en: https://www.researchgate.net/profile/Inder-Kumar-2/publication/348554319_A_review_on_pharmacokinetics_pharmacodynamics_and_clinical_aspects_of_remdesivir_and_favipiravir_for_the_treatment_of_coronavirus_disease/links/6003b07692851c13fe17f5c4/A-review-on-pharmacokinetics-pharmacodynamics-and-clinical-aspects-of-remdesivir-and-favipiravir-for-the-treatment-of-coronavirus-disease.pdf
Byléhn F, Menéndez CA, Pérez-Lemus GR, Alvarado W, De Pablo JJ. Modeling the Binding Mechanism of Remdesivir, Favipiravir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase. ACS Cent Sci [Internet]. 2017 [citado 13 Abr 2021];7(1):164-74. Disponible en: https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c01242
Rezagholizadeh A, Khiali S, SarbaKhsh P, Entezari–Maleki T. Remdesivir for Treatment of Covid-19: an updated systematic review and meta-analysis. Eur J Pharmacol [Internet]. 2021 [citado 13 Abr 2021];897:[aprox. 8 p.]. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014299921000790
Davis M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, et al. Remdesivir in Treatment of Covid-19: A Systematic Benefic-Risk Assessment. Drug Saf [Internet]. 2020 [citado 13 Abr 2021];43(7):645-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255634/pdf/40264_2020_Article_952.pdf
Aleissa MM, Silverman EA, Paredes AL, Nutt CT, Richterman A, Marty F. New Perpective of Antimicrobial Agents: Remdesivir Treatment for Covid-19. Antimicrob Agents Chemother [Internet]. 2020 [citado 13 Abr 2021];65(1):[aprox. 18 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927874/pdf/AAC.01814-20.pdf
Dal-Ré R, Banzi R, Georgin-Lavialle S, Porcher R, Sofat R, Zeitlinger M, et al. Remdesivir for Covid-19 in Europe: will it provide value for money? Comment. Lancet [Internet]. 2021 [citado 13 Abr 2021];9(2):127-28. Disponible en: https://www.sciencedirect.com/sdfe/reader/pii/S2213260020305683/pdf
Xu Y, Barauskas O, Kim C, Babusis D, Murakami E, Kornyeyev D, et al. Off-Target In Vitro Profiling Demostrates that Remdesivir Is a Highly Selective Antiviral Agent. ASM AAC [Internet]. 2021 [citado 13 Abr 2021];65(2):[aprox. 14 p.]. Disponible en: https://journals.asm.org/doi/pdf/10.1128/aac.02237-20
Bhimraj A, Morgan RL, Shumarker AH, Lavergne V, Baden L, Cheg VCC, et al. Infectious Diseases Society of American Guideline on the Treatment and Management of Patients with Covid-19. IDSA [Internet]. 2020 [citado 13 Abr 2021]; Version 4.2.1. Disponible en: https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v9.0.0.pdf
Frediansyanh A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A Systematic Review. Clin. Epidemiology Glob. Health. [Internet]. 2020 [citado 13 Abr 2021];9:123-27. Disponible en: https://www.sciencedirect.com/science/article/pii/S2213398420301810
Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, et al. Pharmacokinetic, Pharmacodynamic, and Drugs Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet [Internet]. 2021 [citado 13 Abr 2021];60:569-83. Disponible en: https://link.springer.com/content/pdf/10.1007/s40262-021-00984-5.pdf
Sherwat A, Murray J, Birnkrant D, Farley J. Combined Cross-Discipline Team Leader, Division Director and ODE Director Summery Review. Center for Drugs Evaluation and Research. Application Number: 214787rig1s000. Summary Review. Gialead Sciences Inc [Internet]. 21 Oct 2020 [citado 13 Abr 2021]; NDA 214787. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000Sumr.pdf
Jaime-Lin HX, Cho S, Meyyur-Aravamudan V, Yu-Sanda H, Palraj R, Molton JS, et al. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection [Internet]. 2020 [citado 13 Abr 2021];49(3):201-10. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778417/pdf/15010_2020_Article_1557.pdf
Killegeros M, Tashima KT, Mylona EK, Rybal N, Flanigan TP, Farmakiotis D, et al. Remdesir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A single Single-Center Experience. Open Forum Infect Dis [Internet]. 2020 [citado 13 Abr 2021];7(10):[aprox. 8 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454852/pdf/ofaa319.pdf
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe Covid-19: a randomised, double blind, placebo-controlled, multicentre trial. Lancet [Internet] 2020 [citado 13 Abr 2021];395:1569-78. Disponible en: http://klinikfarmakoloji.com/sites/default/files/2020-08/remdesivir-wang.pdf
Al-Abdouh A, Bizanti A, Barbarawi M, Jadri A, Kumar A, Fashanu OE, et al. Remdesivir for treatment of Covid-19: A systematic review and meta-analysis of randomized controlled trials. Contemp Clin Trials [Internet]. 2021 [citado 13 Abr 2021];101. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789823/pdf/main.pdf
Kelleni M. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for Covid-19: a Comprenhensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med [Internet]. 2021 [citado 13 Abr 2021];3(4):919-23. Disponible en: https://link.springer.com/content/pdf/10.1007/s42399-021-00824-4.pdf?pdf=button%20sticky
Beigel JH, Tomashek KM, Dodd LE, Metha AK, Zingman BS, Kalil AC, et al. Remdesivir for Treatment of Covid-19- Final Report. N Engl J Med [Internet]. 2020 [citado 13 Abr 2021];383(19):1813-26. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/pdf/NEJMoa2007764.pdf
Musa A, Pendi K, Hashemi A, Warbasse E, Kouyoumjian S, Yousif J, et al. Remdesivir for the Treatment of Covid-19: A Systematic Review of the Literature. West J Emerg Med [Internet]. 2020 [citado 13 Abr 2021];21(4):737-41. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390571/pdf/wjem-21-737.pdf
Spinner CD, Gottlieb RL, Criner GJ, Arribas LJR, Cattelan AM, Viladomiu SA, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderates Covid-19: a Ramdomized Clinical Trial. JAMA [Internet]. 2020 [citado 13 Abr 2021];324(11):1048-57. Disponible en: https://jamanetwork.com/journals/jama/articlepdf/2769871/jama_spinner_2020_oi_200097_1600070022.50408.pdf
Hu WJ, Chang L, Yang Y, Wang X, Xie YC, Shen JS, et al. Pharmacokinetics and tissues Distribuition of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacol. Sin [Internet]. 2020 [citado 13 Abr 2021];42(7):[aprox. 6 p.]. Disponible en: https://www.researchgate.net/profile/Bo-Tan-14/publication/345365827_Pharmacokinetics_and_tissue_distribution_of_remdesivir_and_its_metabolites_nucleotide_monophosphate_nucleotide_triphosphate_and_nucleoside_in_mice/links/5fd897ca299bf140880f8ea9/Pharmacokinetics-and-tissue-distribution-of-remdesivir-and-its-metabolites-nucleotide-monophosphate-nucleotide-triphosphate-and-nucleoside-in-mice.pdf?origin=publication_detail
Patrick-Lê M, Hingrat-Le Q, Jaquet P, Wicky PH, Bunel V, Massias L, et al. Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in Double Lung Transplant Recipient with Covid-19. ASM J [Internet]. 2020 [citado 13 Abr 2021];64(11):e1521-20. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577145/pdf/AAC.01521-20.pdf
Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen DJ, et al. In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters. Int. J. Pharm [Internet]. 2021 [citado 13 Abr 2021];3[aprox. 7 p.]. Disponible en: https://www.sciencedirect.com/science/article/pii/S2590156721000025
Goldman JD, Lye DC, Hui DS, Marks KS, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med [Internet]. 2020 [citado 13 Abr 2021];383(19):1827-37. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/pdf/NEJMoa2015301.pdf
Nies AT, König J, Hofmann U, Kölz C, Fromm MF, Schwab M. Interaction of Remdesivir with Clinically Relevant Hepatic Drugs Uptake Transporter. Pharmaceutics [Internet]. 2021 [citado 13 Abr 2021];13(3):[aprox 8 p.]. Disponible en: https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-00369/article_deploy/pharmaceutics-13-00369-v2.pdf?version=1615451326
Peyko V, Ledd H, Cutrona A. The Safety Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis. Case Rep Infect Dis [Internet]. 2020 [citado 13 Abr 2021]:[aprox. 5 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771254/pdf/CRIID2020-8811798.pdf
Thakare S, Gandhi C, Modi T, Bose S, Deb S, Saxena N, et al. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep [Internet]. 2020 [citado 13 Abr 2021];6(1):206-10. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547837/pdf/main.pdf
Sörgel F, Malin JJ, Hagmann H, Kinzing M, Bilal M, Eichenauer DA, et al. Pharmacokinetics of remdesivir in a Covid-19 patient with end-stage renal disease on intermittent haemodialysis. J Antimicrob Chemother [Internet]. 2020 [citado 13 Abr 2021];76(3):825-27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799013/pdf/dkaa500.pdf
Ackley TW, McManus D, Topal JE, Cicali B, Shah S. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. Antimicrob. Agents Chemother [Internet]. 2021 [citado 1 May 2021];65(2):[aprox. 9 p.]. Disponible : https://journals.asm.org/doi/epub/10.1128/AAC.02290-20
Adapa S, Chenna A, Balla M, Prasad GM, Koduri NM, Doggubati SR, et al. Covid-19 Pandemia Causing Acute Kidney Injury and Impacto in Patients With Chronic Kidney Diseases and Renal Transplantation. J Clin Med Res [Internet]. 2020 [citado 1 May 2021];12(6):352-61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295554/pdf/jocmr-12-352.pdf
Xu Z, Tang Y, Huang Q, Fu Sha, Li X, Lin B, et al. Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with Covid-19. BMC Nephrol [Internet]. 2021 [citado 1 May 2021];22(1):[aprox. 10 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863041/pdf/12882_2021_Article_2244.pdf
Kalil AC, Patterson ACK, Mehta AK, Tomashek KM, Ghazaryan WV, Marconi VC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med [Internet]. 2021 [citado 1 May 2021];384(9):795-807. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745180/pdf/NEJMoa2031994.pdf
Ghosh CK, Hasan SMA, Dey S. Remdesivir Induced Liver Injury and Severe Covid-19 Infection. Am. J. Med [Internet]. 2020 [citado 1 May 2021];8(6):285-88. Disponible en: https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20200806.18.pdf
Téllez L, Martín-Mateos RM. Actualización en Covid-19 y enfermedades hepáticas. Gastroenterol
Hepatol [Internet]. 2020 [citado 1 May 2021];43(8):472-80. Disponible en: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-pdf-S0210570520302417
Nardo AD, Gleixner MS, Bakail M, Dixon ED, Lax SF, Trauner M. Phatophysiological Mechanisms of Liver Injury in Covid-19. Liver Int [Internet]. 2020 [citado 1 May 2021];41(1):[aprox 13 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753756/pdf/LIV-9999-na.pdf
Vitiello A, Porta RL, D´Aiuto V, Ferrara F. The risks of liver injury in Covid-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J [Internet]. 2021 [citado 1 May 2021];11(1):[aprox. 11 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838235/pdf/43066_2021_Article_82.pdf
Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of Pharmacology, Pre-Clinical Data and Emerging Clinical Experience for Covid-19. Pharmacotherapy [Internet]. 2020 [citado 1 May 2021];40(7):659-71. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283864/pdf/PHAR-9999-na.pdf
MohammadReza-Hashemian S, Farhadi T, Akbar AV. A Review on Remdesivir: A Possible Promising Agent for the Treatment of Covid-19. Drug Des Devel Ther [Internet]. 2020 [citado 1 May 2021];2020(14):3215-22. Disponible en: https://www.tandfonline.com/doi/full/10.2147/DDDT.S261154
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Raymel Arceo Naranjo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
